Isoprostane in systemic sclerosis: A systematic review and meta-analysis

References

• Nourooz-Zadeh J. Key issues in F2-isoprostane analysis. Biochem Soc Trans. 2008;36:1060–5.
   PubMed Web of Science ®Google Scholar
• Praticò D, Barry OP, Lawson JA, Adiyaman M, Hwang SW, Khanapure SP, et al. iPF2alpha-I: An index of lipid peroxidation in humans. Proc Natl Acad Sci USA. 1998;95:3449–54.
   PubMed Web of Science ®Google Scholar
• Li H, Lawson JA, Reilly M, Adiyaman M, Hwang SW, Rokach J, et al. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine. Proc Natl Acad Sci USA. 1999;96:13381–6.
   PubMed Web of Science ®Google Scholar
• Roberts LJ, II, Moore KP, Zackert WE, Oates JA, Morrow JD. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans. J Biol Chem. 1996;271:20617–20.
   PubMed Web of Science ®Google Scholar
• Schwedhelm E, Tsikas D, Durand T, Gutzki FM, Guy A, Rossi JC, et al. Tandem mass spectrometric quantification of 8-iso-prostaglandin F2alpha and its metabolite 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2alpha in human urine. J Chromatogr B Biomed Sci Appl. 2000;744:99–112.
   PubMed Web of Science ®Google Scholar
• Nourooz-Zadeh J, Cooper MB, Ziegler D, Betteridge DJ. Urinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress. Biochem Biophys Res Commun. 2005;330:731–6.
   PubMed Web of Science ®Google Scholar
• Awad JA, Morrow JD, Takahashi K, Roberts LJ. II. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem. 1993;268:4161–9.
   PubMed Web of Science ®Google Scholar
• Chiabrando C, Rivalta C, Bagnati R, Valagussa A, Durand T, Guy A, et al. Identification of metabolites from type III F2-isoprostane diaste-reoisomers by mass spectrometry. J Lipid Res. 2002;43:495–509.
   PubMed Web of Science ®Google Scholar
• Yan Z, Mas E, Mori TA, Croft KD, Barden AE. A significant proportion of F2-isoprostanes in human urine are excreted as glucuronide conjugates. Anal Biochem. 2010;403:126–8.
   PubMed Web of Science ®Google Scholar
• Ames PRJ, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology. 1999;38:529–34.
   PubMed Web of Science ®Google Scholar
• Avalos I, Chung CP, Oeser A, Milne GL, Morrow JD, Gebretsadik T, et al. Oxidative stress in systemic lupus erythematosus: Relationship to disease activity and symptoms. Lupus. 2007;16:195–200.
   PubMed Web of Science ®Google Scholar
• Ames PR, Tommasino C, Alves J, Morrow JD, Iannaccone L, Fossati G, et al. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: A pilot study. Lupus. 2000;9:688–95.
   PubMed Web of Science ®Google Scholar
• Ferro D, Saliola M, Meroni PL, Valesini G, Caroselli C, Praticò D, et al. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: Effect of antioxidant treatment. J Thromb Haemost. 2003;1:523–31.
   PubMed Web of Science ®Google Scholar
• Sagun G, Oguz A, Mesci B, Isbilen B, Kavala M, Keskin H, et al. Levels of F2 isoprostane in Behcet's disease: Correlation with cardiometabolic risk factors. Redox Rep. 2015;20:223–7.
   PubMed Web of Science ®Google Scholar
• Łuczaj W, Gindzienska-Sieskiewicz E, Jarocka-Karpowicz I, Andrisic L, Sierakowski S, Zarkovic N, et al. The onset of lipid peroxidation in rheumatoid arthritis: Consequences and monitoring. Free Radic Res. 2016;50:304–13.
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:73–80.
   PubMed Web of Science ®Google Scholar
• Luo JY, Liu X, Jiang M, Zhao HP, Zhao JJ. Oxidative stress markers in blood in systemic sclerosis: A meta-analysis. Mod Rheumatol. 2017;27:306–14.
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Kom GD, Salvat-Melis M, Renversez JC, McCord G, Boignard A, et al. Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis. Free Radical Biol Med. 2006;40:1732–7.
   PubMed Web of Science ®Google Scholar
• Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology. 2006;45:815–18.
   PubMed Web of Science ®Google Scholar
• Volpe A, Biasi D, Caramaschi P, Mantovani W, Bambara LM, Canestrini S, et al. Levels of F2-isoprostanes in systemic sclerosis: Correlation with clinical features. Rheumatology. 2006;45:314–20.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med. 2009;1514:65–94.
   Google Scholar
• Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. PNAS. 1990;87:9383–7.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomized studies in meta-analyses. Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.htm [last accessed 10 May 2018].
   Google Scholar
• Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. Br Med J. 2001;342:d549.
   Google Scholar
• Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. Br Med J. 2006;333:597–600.
   PubMed Web of Science ®Google Scholar
• Tang JL, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol. 2000;53:477–84.
   PubMed Web of Science ®Google Scholar
• Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD. Evidence of free radicalmediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 1996;39:1146–50.
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Marpeau C, Carpentier PH, Imbert B, Hunt M, Stanke-Labesque F, et al. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum. 2001;44:1143–8.
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Carpentier PH, Imbert B, Cachot S, Stanke-Labesque F, Bessard J, et al. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: Effect of cold exposure. Arthritis Rheum. 2002;46:1319–23.
   PubMedGoogle Scholar
• Erre GL, De Muro P, Dellacà P, Fenu P, Cherchi GM, Faedda R, et al. Iloprost therapy acutely decreases oxidative stress in patients affected by systemic sclerosis. Clin Exp Rheumatol. 2008;26:1095–8.
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
   PubMedGoogle Scholar
• Janssen LJ, Premji M, Netherton S, Coruzzi J, Lu-Chao H, Cox PG. Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. Br J Pharmacol. 2001;132:127–34.
   PubMed Web of Science ®Google Scholar
• Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int. 1999;56:471–8.
   PubMed Web of Science ®Google Scholar
• Mostmans Y, Cutolo M, Giddelo C, Decuman S, Melsens K, Declercq H, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review. Autoimmun Rev. 2017;16:774–86.
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–15.
   PubMed Web of Science ®Google Scholar
• Hansson P, Barregård L, Halltorp M, Sibthorpe S, Svelander C, Sandberg AS, et al. Habitual high intake of fatty fish is related to lower levels of F2-isoprostane in healthy women. Nutrition. 2015;31:847–52.
   PubMed Web of Science ®Google Scholar
• Kitano S, Hisatomi H, Hibi N, Kawano K, Harada S. Improved method of plasma 8-Isoprostane measurement and association analyses with habitual drinking and smoking. World J Gastroenterol. 2006;12:5846–52.
   PubMed Web of Science ®Google Scholar
• Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198–203.
   PubMed Web of Science ®Google Scholar
• Spadoni T, Svegliati Baroni S, Amico D, Albani L, Moroncini G, Avvedimento EV, et al. A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol. 2015;67:1611–22.
   PubMed Web of Science ®Google Scholar